A smart policy like the ‘PILLS Act’ would prioritize domestic production of essential generics. It’s precisely the market signal needed to attract serious investment and rebuild the industry at home.
As the leading organization advocating for reshoring the generic drug industry, CPA’s submission documents how extreme overreliance on foreign pharmaceutical supplies—especially active pharmaceutical ingredients (APIs) and critical injectable drugs from China and India—poses an urgent threat to U.S. national security and patient safety.
President Trump’s Executive Order is a bold, necessary move to rebuild America’s pharmaceutical industry and protect our citizens.
Tariffs on pharmaceutical companies isn’t just good economic policy — it benefits national security and public health.
The United States is amid a dangerous drug shortage that endangers patients, undermines our health care system and exposes a deep vulnerability to national security. America’s overwhelming reliance on foreign manufacturers for generic drugs is at the center of it.
The National Institutes of Health (NIH) is today the main source of new drugs in this country – indeed the world, because America leads in the field. It has a critical importance to America’s health. Less well known is its huge, positive, economic impact.
It’s been a rough start to 2025 for Indian pharmaceutical giants. Four of India’s biggest generic drug producers issued product recalls in the last three months.
Strong federal investment in the National Science Foundation and National Institutes of Health is vital for American innovation, economic growth, and national security.
In 2024, China and India accounted for 57.6% of total U.S. pharmaceutical imports by weight, highlighting the potential risks associated with such reliance. Growing U.S. dependence on China and India for widely-used generic pharmaceutical products creates serious risks to national security and patient safety when drugs are in short supply, or ineffective.
CPA announced key leadership changes as CEO Michael Stumo steps down to take on a new role in the Trump administration. Jon Toomey has been elevated as President of CPA to lead the organization and Nick Iacovella has been promoted to Executive Vice President.
